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INTRODUCTION
Lipoprotein(a) [Lp(a)] is composed of a low density lipoprotein
(LDL) particle with apolipoprotein (a) [apo(a)]. Apo(a) is a ho-
molog of plasminogen that contains 10 different types of plasmi-
nogen kringle-4-like repeats (kringle-4 types 1 through 10), sug-
gesting its relation to anti - fibrinolytic properties. Many studies
have shown elevated plasma Lp(a) levels as a risk factor for a variety
of atherosclerotic and thrombotic diseases including peripheral
vascular disease, thromboembolism, and coronary heart disease
(1, 2). According to the Adult Treatment Plan (ATP) III guidelines
(3), Lp(a) was classified as an “emerging” risk factor for cardiovas-
cular disease. Plasma levels of Lp(a) are under genetic control
and there is no specific agent to reduce plasma Lp(a). Lipid- low-
ering agents, statins, have little or no effect on plasma Lp(a) levels.
Niacin and estrogen reduce plasma Lp(a) levels, but only slightly.
In addition to lowering Lp(a), niacin has lowering effects on LDL-
cholesterol, triglycerides and remnant cholesterol levels. Thus,
the benefit of niacin on CVD cannot be mediated only by Lp(a)
reduction. Therefore, highly specific and potent Lp(a) lowering
drugs are awaited to clarify the Lp (a) function.
It is challenging to prove that Lp(a) lowering can reduce car-
diovascular risk in patients with high Lp(a) levels as well as in
animal models. To prove drug effect on Lp(a) and its function,
however, the use of animal models is difficult because of the un-
usual species distribution of Lp(a). Lp(a) is only present in humans
and primates, and is absent in common laboratory animals such as
mice and pigs (4). In the present study we used double transgenic
mice of human Lp(a), and studied a novel Lp(a) lowering drug on
vascular injury models to study atherogenic action of Lp(a).
METHODS
Drugs
Lp(a) lowering compound, D-47, produced by Dr. K. Ogawa, a
co-author of this paper, was used to study Lp(a) function. D-47 is
a pharmaceutical formulation composition of solid dispersion con-
tained the arginine salt of S-2E [(S)(+)-4 -((4- tert -Butylphenyl) -
2 -oxo-pyrrolidine- 4-yl) methoxybenzoic acid] (5), with “soluplusR”
(BASF) as the water soluble polymer, in the ratio of one to two. The
water solubility and oral absorption of S-2Ewere improved by this
solid dispersion, D-47, which was prepared by solvent method as
described below.
The mixture of S-2E arginine salt (30 g) and soluplus (60 g)
was dissolved in methanol 250 ml at around 50 and then evapo-
rated the solvent under reduced pressure. Into the residue, ethyl
ether 100 ml was added and then evaporated the solvent. The final
residue in the vessel was scraped together and then dried under
reduced pressure at room temperature to obtain the D-47 (88 g).
The amorphous state of S-2E arginine salt in D-47 was confirmed
by X-ray powder diffraction analysis and DSC analysis.
Animal
Eight male Lp(a) transgenic mice were divided into two groups,
control (n=4) and treated groups (n=4). Lp(a) transgenic mice
were kindly provided by R. Morishita, Osaka University, Japan
(6-8). Because apo(a) is present only in humans, primates and
hedgehogs, we used Lp(a) transgenic mice that were generated
by crossing human apo(a) transgenic mice (7) and human ApoB
transgenic mice (8) to test the drug effects. The mice had free
access to water and standard chow (standard non-purified diet,
Oriental Yeast, Tokyo, Japan). Mice in the treated group were
added D-47(30 mg/kg/day)to the standard chow from 10 weeks
(i.e. 2 weeks before surgery) until 4 weeks after surgery. The mice
in the control group were treated standard chow which was added
only soluplus without D-47. At 12 week, vascular injury was per-
formed to both groups. The experiments were approved by the
Ethical Committee for Animal Experiments of the Tokushima
University Graduate School of Medicine.
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Production of vascular injury
Vascular injury was induced in mice as described previously
(9, 10). A straight spring wire (0.38 mm in diameter, No.C-SF-15-
15, COOK) was inserted into the femoral artery and left in place for
1 minute to denude and dilate the artery. Blood flow was restored.
Artery was collected at day 28 after the injury. Mice were sacrificed
by deep anesthesia and blood was sampled for analysis of lipid
profile. For morphometric analysis, the femoral arteries were har-
vested at 4 weeks after the injury. To investigate the degree of
neointimal formation, the proximal segments of the injured arter-
ies were fixed in paraformaldehyde, embedded in paraffin, sec-
tioned at 5 μm thickness, and stained with Elastica van Gieson.
Neointima and media areas were measured by a computer-assisted
image analyzer using Image J Software (BioArts).
Measurement of Lipid profile
Lp(a) was measured by latex agglutination turbidimetry using
a commercial kit (COBAS MIRA, Sanwakagaku Co. Japan). Total
cholesterol was measured by Ultra. Violet -End (UV-End) method
using cholesterol dehydrogenase, and triglyceride was measured
by enzymatic determination using the enzyme glycerol phosphate
oxidase (GPO) after hydrolysisby lipoprotein lipase.
Statistics
The results were expressed as the meansstandard deviations.
The data were compared two groups using Student’s t - test. As
Lp(a) levels were variable in each animal, we also used nonpara-
metric comparison (Mann-Whitney U test) between two groups.
Values of P0.05 were considered statistically significant.
RESULTS
Fig 1 shows the change of the lipid profile and blood glucose
levels by the D-47. Treatment of the drug markedly reduced the
blood levels of Lp(a) (30.312.7 mg/dL in the control group vs
5.51.3 mg/dL in the treated group, p=0.047 in U-test), and tri-
glyceride (514.034.2 mg/dL vs 385.529.3 mg/dL, p=0.003).
Blood levels of total cholesterol were not altered significantly by
D-47 (279.020.1 mg/dL vs 284.015.3 mg/dL, p=0.721). Blood
glucose levels were not different between two groups, either
(251.747.4 mg/dL vs 327.564.7 mg/dL, p=0.149).
Fig 2 shows the comparison of neointima formation after vascular
injury. The neointima areas, which are defined as the area of the
space between the lumen and internal elastic lamina, were increased
in control mice. In contrast, treatment with D-47 attenuated the
neointima areas in transgenic mice (Figure 2A and B), although the
difference did not reach the level of statistical significance (p=
0.175). The ratio of the neointima thickness to the media thickness
tended to be smaller in the D-47 treated mice than in the control
mice (2.120.94 vs 1.340.36, p=0.173).
DISCUSSION
Lp(a) have been thought to be a cardiovascular risk factor. This
study demonstrated that a novel Lp(a) lowering drug, D-47, suc-
cessfully decreased plasma levels of Lp(a) and possibly inhibited
neointima formation in Lp(a) transgenic mice. The results indicate
that we can modulate plasma Lp(a) levels by pharmacologic agents
and inhibit atherogenic properties by reducing plasma levels of
Lp(a).
Lp(a) is a low density lipoprotein (LDL) particle which is at-
tached to the polypeptide, apo(a). Apo(a) has unique structural
properties, i.e., plasminogen kringle-4 - like repeats (1, 2). Because
of the high degree of homology between apo(a) and plasminogen,
Lp(a)/apo(a) can competitively inhibit tissue-type plasminogen
activator -mediated plasminogen activation on fibrin surfaces, al-
though the mechanism of inhibition by apolipoprotein(a) remains
controversial. Lp(a) and apo(a) also have been thought to enhance
the proliferation of human vascular smooth muscle cells (VSMCs)
by inhibiting the activation of plasminogen to plasmin (11, 12).
Further mechanisms have been shown to involve atherogenesity
of this lipoprotein.
Lipoprotein apheresis is very efficient in decreasing Lp(a) con-
centrations. A single apheresis session can acutely decrease Lp(a)
by approximately 60-75% and weekly or biweekly performed aphere-
sis results in considerably decreased Lp(a) concentrations. In lon-
gitudinal cohort study, Jaeger BR et al. (13) showed combined
lipoprotein apheresis and lipid- lowering medication prevent major
adverse coronary events more efficaciously than lipid- lowering
medication alone. Similarly, the Pro(a)LiFe-study confirmed with
a prospective multicenter design that lipoprotein apheresis can
effectively reduce Lp(a) plasma levels and prevent cardiovascular
events (14). Ezhov MV et al. (15) also showed that isolated extra-
corporeal Lp(a) elimination over an 18 months period produced
regression of carotid intima-media thickness in stable CHD pa-
tients with high Lp(a) levels. Although lipoprotein apheresis also
decreases other atherogenic lipoproteins, such as oxydized LDL,
these results suggest possibilities that lowering Lp(a) levels might
reduce adverse coronary events.
Lp(a) is not present in experimental animal and Lp(a) is com-
posed of a moiety with apolipoprotein B-100 (ApoB-100). Expres-
sion of apo(a) alone in mice does not form a complex with endo-
genous mouse LDL, indicating that human LDL is also required
to study its function. Therefore, we have to use double transgenic
mice with human apo(a) and human LDL to test the Lp(a) function.
The previous studies showed that mice expressing the apo(a) gene
developed atherosclerosis (16, 17). Using this model animal,
Kyutoku M et al. (18) reported that DNA vaccine against apo(a)
could significantly inhibit neointima formation in carotid artery
ligation and concluded that the pro-atherosclerotic actions of Lp(a)
could be prevented by reducing Lp(a) levels.
More recently, Evolocumab, a monoclonal antibody (mAb) to
proprotein convertase subtilisin/kexin type 9 (PCSK9), decreases
Lp(a) (19). The reduction of Lp(a) levels are thought to be sec-
ondary to low circulating LDL due to the increased LDL receptors
by this drug.
Fig. 1 Effect of D-47 on lipids profile.
Serum levels of lipoprotein (a) were markedly decreased in D-47 treated
mice compared to the control mice. Serum total cholesterol and glucose
levels were not different between two groups, although serum levels of
triglyceride were greater in the D-47 treated mice.
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Unfortunately, the high degree of homology between apo(a) and
plasminogen has been difficult in the development of drugs against
Lp(a). The drugs which selectively inhibit Lp(a) is particularly at-
tractive to clinical application. D-47 is a novel drug which selec-
tively lowers serum Lp(a) levels. Vascular injury model is a useful
tools for investigating the mechanism of vascular remodeling be-
cause they invoke leukocyte adhesion and infiltration, proliferation
of smooth muscle cells and neointima formation (9, 10). Using this
model and the double transgenic mice, we have shown that D-47
lowered serum levels of Lp(a) and possibly reduced vascular inflam-
mation and neointima formation after vascular injury. Together
with previous studies, the results of the present study suggest
lowering of Lp(a) might reduce cardiovascular diseases related
to high Lp(a).
This is a preliminary study of a new drug and the numbers of the
studied animals were small, by which we could not obtain the sta-
tistical significance in reduction of neointima formation. Further-
more, the study was tested in model animals which are not identical
to human. Therefore, we do not know whether we can extrapolate
the results of the study to human with high Lp(a) levels. Further
studies will be waited. The results of this study, however, suggest
a novel therapeutic strategy for the treatment of cardiovascular
diseases that are related to high Lp(a) levels.
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